No introductions necessary: A TCR upstart with deep-pocket backers partners with one of the new players in the hot gene editing field

When Affini-T arrived on the scene a few weeks ago, it had most of the essential elements needed by any biotech upstart.

There were high …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

No in­tro­duc­tions nec­es­sary: A TCR up­start with deep-pock­et back­ers part­ners with one of the new play­ers in the hot gene edit­ing field